Start your transformation today with a science-backed, clinician-guided weight loss plan. Personalized nutrition, lifestyle support, and optional GLP-1 therapy designed to help you reach your goals safely and sustainably. Results vary from person to person.
Kickstart your weight loss journey with a personalized, medically supervised program. Clinician-guided plans, nutrition support, and proven treatments help make weight loss more manageable. Reserve Your Spot Today!
Now available for new patients starting at just $179.
Compounded medication offers lower cost, flexible dosing, and access without insurance barriers. Compounded medications are prepared by licensed pharmacies and are not FDA-approved.
Schedule AppointmentSemaglutide is the active ingredient in the FDA-approved medications Wegovy® and Ozempic®. Elevera Health may prescribe brand-name or compounded semaglutide depending on your needs; compounded medications are prepared by licensed pharmacies and are not FDA-approved. Semaglutide is a once-weekly injection you give yourself at home, and our team shows you how and supports you along the way.
Semaglutide is a GLP-1 agonist and was first approved in the U.S. in 2017 to improve blood sugar control in patients with type 2 diabetes. Once-weekly higher-dose semaglutide (Wegovy®) is FDA-approved as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with obesity or overweight with a weight-related condition.
Semaglutide, a medicine that raises the body’s levels of glucagon-like peptide, is typically administered subcutaneously once per week during the patient’s treatment. GLP-1 is a vital factor in controlling blood sugar and weight. It aids in appetite suppression through the brain and delays stomach emptying to heighten the feeling of fullness.
GLP-1 is a hormone produced in the small intestine that stimulates insulin secretion and inhibits glucagon secretion, thereby lowering blood sugar. Shorter-acting agonists of the GLP-1 receptor are particularly effective at lowering post-meal glucose spikes, whereas longer-acting GLP-1 agonists have a balanced effect on lowering post-meal glucose levels as well as fasting glucose levels.This GLP-1 agonist has demonstrated beneficial effects on hyperglycemia in addition to decreased appetite and reduced daily caloric intake.
Patients with obesity and excess weight who have a BMI of 30 or higher, or a BMI of 27 or higher with an additional obesity-related health issue, are eligible for Semaglutide. Semaglutide alone is unlikely to achieve the desired result of weight reduction; it is meant to support a routine of increased physical activity and a low-calorie diet.
Â
A consistent physical exercise routine, nutritional assistance, and good eating practices are necessary for weight loss with Semaglutide. The program starts with an initial dietary consultation followed by an initial medication consultation to examine your medical history, talk about your weight reduction objectives, and assess if Semaglutide is the right therapy for you.
Â
All appointments are telehealth visits. Serving patients anywhere in Virginia, Maryland, West Virginia and Washington, DC.
Book Now